Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

New Line of Single-Use Bags Meets Stringent Requirements of the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
A major global supplier of laboratory products for the biopharmaceutical industry has begun marketing a new range of single-use bags in a multitude of sizes and shapes.

Sartorius Stedim Biotech (Goettingen, Germany) has announced the release of its line of Flexsafe single-use bags. Flexsafe, which is based on S80, a multilayer, proprietary polyethylene (PE) film, was developed in close collaboration with resin and film suppliers. The PE film is 400 micrometers thick, making Flexsafe one of the strongest and most flexible bags currently on the market.

Optimization of resin formulation, complete control of raw materials quality, the extrusion process, and bag assembly guarantee lot-to-lot consistent cell growth performance of even the most sensitive cell lines.

Flexsafe bags are safe and easy to manage, even for the most demanding applications such as liquid shipping and large-scale stirred bioreactors. Batch-to-batch consistent extractables and leachables profiles, which support drug manufacture throughout all processes from clinical development to commercial supply, guarantee that initial extractable and leachable qualification data will remain valid for every operation involving single-use Flexsafe bioprocess products.

"Flexsafe represents a completely new generation of single-use bags," said Stefan Schlack, senior vice president marketing and product management at Sartorius Stedim Biotech. "They offer our customers consistent cell growth as well as extraordinary robustness and flexibility. In addition a sustainable supply chain and consistent film throughout the entire manufacturing process is guaranteed. Every single one of these benefits sets a new benchmark. Being unique in all of them makes us very proud.”

Initially Sartorius Stedim Biotech is launching Flexsafe RM bags (1–200 liters) and small bags for validation purposes. Bags for single use bioreactors BIOSTAT STR (50–2,000 liters) and additional applications such as storage, mixing, shipping, freezing and thawing will be introduced over the coming months.

Related Links:

Sartorius Stedim Biotech 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

Molecular Pathway Decreases Cell Adhesion and Initiates Metastasis

A recent paper outlined a molecular pathway that enables lung cancer cells to migrate away from the site of the primary tumor and become established in other parts of the body. Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) linked a virtual alphabet soup of genes and their protein products... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.